Cancer is a growing disease as this pathology represents 8 millions death per year in the whole world.
Radiotherapy is actually used for 60% of cancer treatments even if this technique exhibits several drawbacks concerning the lack of reliable real-time dose monitoring.
These limits lead to significant therapeutic threshold effects, as 5% of dose variation give rise to 20% variation of the tumor control probability and 30% variation of the normal tissue complication probability.
NANOPTiX technology has been developed to overcome these obstacles by adding reliable and precise tool for ionizing radiation monitoring.
From decade ago, in vivo dosimetry has became a regulatory standard to monitor the adequacy between real dose received by patients versus prescribed dose. This obligation concerns only the beams technically measurables and highlights strong needs for this type of technologies.
The NANOPTiX technology consists of a inert, passive and compact fiber probe.
Thanks to the particular structural assembling of materials, this technology lifts the well known locks of the fiber probes. This allows to obtain a small size fiber (< 100 µM) with high signal quality.
Small size (optical fiber size < 100 µM), allowing to minimize invasive character on the patient while conserving high efficiency
NANOPTiX fibers have a high sensibility and spatial resolution by their multi-probe sensors properties
These disposable fibers have potentially a low cost.
MARKETS AND APPLICATIONS
Medicine - radiotherapy :
Preliminary « physical probes »
Ready and start to be tested in clinical environment by prototyping medical probes
University of Franche-Comté - CNRS
French Patent pending
+33 (0)6 17 06 68 07